李国德,黄淑云,谢海群,陈静娟,彭伟英
LI Guode,HUANG Shuyun,XIE Haiqun,CHEN Jingjuan,PENG Weiying

• 1:广东省佛山市第一人民医院神经内科

摘要(Abstract)：

目的探讨左旋氨氯地平联合他汀类药物治疗对急性高血压性脑梗死患者神经功能的影响。方法 2014-01~2014-12在本院神经内科住院并完成至少11个月随访的急性高血压性脑梗死患者209纳入研究,随机分为2组:A组(苯磺酸左旋氨氯地平联合阿托伐他汀钙)108例;B组(贝那普利联合阿托伐他汀钙)101例。观察并记录血压、NIHSS评分,(分别在卒中第14天、第6个月和终点评估)。结果与发病14 d的NIHSS评分相比,2组6个月及11~12个月NIHSS评分均有显著降低,组内比较差异有统计学意义(P<0.05),与B组相比,A组NIHSS评分更低,组间比较差异有统计学意义(P<0.05)。结论对于急性高血压性脑梗死、不伴有糖尿病及肾功能不全的患者,钙离子拮抗剂降压联合他汀类药物治疗,对患者的预后优于使用肾素血管紧张素转换酶抑制剂联合他汀类药物治疗。
OBJECTIVE To explore the impact of sinistral amlodipine combined statins treatment on the neural function of patients with acute hypertensive cerebral infarction,and to compare the difference of sinistral amlodipine and benazepril combined statins in treatment of patients with acute hypertensive cerebral infarction. METHODS A total of 209 acute hypertensive cerebral infarction patients were included in the study,who hospitalized in department of neurology in January 2014 to December 2014 and completed at least 11 months 'follow-up. They were randomly divided into 2 groups: group A( benzene sulfonic acid amlodipine combined atorvastatin calcium) 108 cases and group B( benazepril combined atorvastatin calcium) 101 cases. The blood pressure,NIHSS score( 14 d,6 months,and the end of stroke assessment) etc. were observed and recorded. RESULTS In the 2 groups,compared with the 14 days ' NIHSS score,the NIHSS score of 6 months and 11-12 months were lower,and the difference was statistically significant( P < 0. 05); and compared with group B,NIHSS score of group A was lower,the difference had statistically significance( P < 0. 05). CONCLUSION For patients with acute hypertensive cerebral infarction,without diabetes and renal insufficiency,calcium antagonists combined statin therapy was superior to renin angiotensin converting enzyme inhibitors combined statin therapy in the prognosis.

关键词(KeyWords)： 高血压;急性脑梗死;神经功能缺损;NIHSS评分
high blood pressure;acute cerebral infarction;nerve function defect;NIHSS score

Abstract:

Keywords:

基金项目(Foundation): 广东省药学会科学研究基金(2013X13)

作者(Author): 李国德,黄淑云,谢海群,陈静娟,彭伟英
LI Guode,HUANG Shuyun,XIE Haiqun,CHEN Jingjuan,PENG Weiying

参考文献(References)：

• [1]Schiffrin EL.Progress in secondary prevention of stroke with PROGRESS.The perindopril protection against recurrent stroke study[J].Curr Hypertens Rep,2002,4(1):39-40.
• [2]Group PC.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack[J].Lancet,2001,358(9287):1033-1041.
• [3]Schrader J,Lüders S,Kulschewski A,et al.Morbidity and Mortality After Stroke,Eprosartan Compared with Nitrendipine for Secondary Prevention:principal results of a prospective randomized controlled study(MOSES)[J].Stroke,2005,36(6):1218-1226.
• [4]Amarenco P,Benavente O,Goldstein LB,et al.Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL)trial by stroke subtypes[J].Stroke,2009,40(4):1405-1409.
• [5]Flint AC,Kamel H,Navi BB,et al.Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival[J].Stroke,2012,43(1):147-154.
• [6]Montecucco F,Quercioli A,Mirabelli-Badenier M,et al.Statins in the treatment of acute ischemic stroke[J].Curr Pharm Biotechnol,2012,13(1):68-76.
• [7]NíChróinín D,Asplund K,Sberg S,et al.Statin therapy and outcome after ischemic stroke:systematic review and meta-analysis of observational studies and randomized trials[J].Stroke,2013,44(2):448-456.
• [8]Salat D,Ribosa R,Garcia-Bonilla L,et al.Statin use before and after acute ischemic stroke onset improves neurological outcome[J][J].Expert Review of Cardiovascular Therapy,2014,7(10):1219-1230.
• [9]Lakhan SES,Bagchi S,Hofer M,et al.Statins and clinical outcome of acute ischemic stroke:a systematic review[J].Int Arch Med,2010,3:22.
• [10]Jay.AVALON-AWC:高血脂和高血压患者应用阿托伐他汀和氨氯地平时动脉壁的顺应性研究[J].世界核心医学期刊文摘:心脏病学分册,2005(8):12-13.
• [11]Ratz Bravo AE,Krahenbühl-Melcher A,Krahenbühl S,et al.Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-Co A Reductase Inhibitor Therapy[J].Drug Safety,2005,28(3):263-275.